gold-peptide-firming-maskgold-peptide-firming-mask
EGFR-binding peptides are short amino acid sequences designed to interact with the Epidermal Growth Factor Receptor (EGFR). These peptides are of significant interest in biomedical research, particularly for targeted drug delivery and cancer therapy. By specifically binding to EGFR, which is often overexpressed on the surface of various cancer cells, these peptides can deliver therapeutic agents directly to tumor sites, minimizing systemic toxicity. The development and application of EGFR-binding peptides represent a sophisticated approach to harnessing molecular recognition for precise therapeutic interventions.
The Epidermal Growth Factor Receptor (EGFR) is a transmembrane protein that plays a crucial role in cell growth, proliferation, and differentiation. When its natural ligands, such as epidermal growth factor (EGF), bind to the extracellular domain of EGFR, it leads to receptor dimerization and subsequent activation of intracellular signaling pathways. Aberrant EGFR signaling is implicated in the development and progression of numerous cancers.
EGFR-binding peptides are engineered or identified to specifically recognize and bind to EGFR作者：H Hossein-Nejad-Ariani·2019·被引用次数：120—Peptide22 is a promisingEGFRspecific TNBC cellbinding peptidethat can be conjugated directly to a chemotherapeutic drug or to nanoparticles for targeted .... This binding can occur through various mechanisms, including targeting the ligand-binding domain, the dimerization interface, or other functional regions of the receptor. The specificity and affinity of these peptides are critical for their effectiveness in therapeutic applications. Researchers have employed diverse strategies, such as computational design, phage display, and ribosome display, to discover and optimize these peptide sequences作者：M Hamzeh‐Mivehroud·2012·被引用次数：42—Ligand-docking calculations.Peptidesselected from phage display experiments were docked into thebindingsite ofEGFRusing the gold program..
The primary application of EGFR-binding peptides lies in targeted cancer therapy.Identification of a novel peptide ligand for the cancer ... By conjugating these peptides to cytotoxic drugs, nanoparticles, or imaging agents, researchers aim to create highly specific delivery systems.作者：PP Than·2024·被引用次数：5—Selective targeting of cancer cells via overexpressed cell-surface receptors is a promising strategy to enhance chemotherapy efficacy and ...
* Drug Delivery: When an EGFR-binding peptide is linked to a chemotherapeutic agent, it can selectively bind to cancer cells expressing EGFR. This targeted binding facilitates the internalization of the drug into the cancer cell, thereby increasing its concentration at the tumor site and reducing exposure of healthy tissues.作者：L Huang·2025·被引用次数：2—Furthermore, reportedEGFR-targetingpeptideswere developed by different groups, and their amino acid sequences and structural designs varied significantly. This approach is particularly promising for treating cancers like triple-negative breast cancer (TNBC), where EGFR is often overexpressed.
* Imaging and Diagnostics: EGFR-binding peptides can also be used as targeting moieties for diagnostic agents. By attaching imaging probes (e.g.Novel EGFR-targeted strategy with hybrid peptide against ..., radioactive isotopes or fluorescent dyes) to these peptides, researchers can develop methods for non-invasively visualizing tumors that overexpress EGFR, aiding in diagnosis and monitoring treatment response.
* Inhibition of EGFR Signaling: Some EGFR-binding peptides are designed to directly inhibit EGFR function. They might interfere with ligand binding, prevent receptor dimerization, or destabilize the receptor itself, thereby blocking downstream signaling pathways that drive cancer growth.p00533 · egfr_human
The design of effective EGFR-binding peptides involves several key considerations:
* Specificity and Affinity: Peptides must exhibit high specificity for EGFR and a strong binding affinity to ensure efficient targeting and minimize off-target effectsNovel Cyclic Peptides for Targeting EGFR and EGRvIII ....
* Stability and Pharmacokinetics: The peptides should be stable in biological environments and possess favorable pharmacokinetic properties, allowing them to reach the target site and remain active for a sufficient duration.
* Delivery Mechanisms: For therapeutic applications, peptides are often incorporated into larger constructs, such as drug conjugates or nanoparticles, to enhance their delivery, stability, and therapeutic payload.
* Computational Design: Advanced computational methods allow for the design of peptides with predicted binding affinities and specific interaction patterns with EGFR作者：PP Than·2024·被引用次数：5—A Conjugate of anEGFR-Binding Peptideand Doxorubicin Shows Selective Toxicity to Triple-Negative Breast Cancer Cells. Click to copy article linkArticle link .... This in silico approach can accelerate the discovery process.
* Screening Techniques: Methods like phage display enable the screening of large libraries of peptides to identify those with the desired binding characteristics to EGFR.
Despite the significant promise of EGFR-binding peptides, several challenges remain. These include optimizing peptide stability, ensuring efficient delivery to solid tumors, overcoming potential immune responses, and developing cost-effective manufacturing processes. Future research will likely focus on developing more sophisticated peptide designs, exploring novel conjugation strategies, and integrating these peptides into multi-modal therapeutic approaches for enhanced efficacy in treating various cancersTargeted cancer treatment using a novel EGFR-specific Fc- .... The continued exploration of EGFR-binding peptides holds substantial potential for advancing precision medicine and improving patient outcomes.
Join the newsletter to receive news, updates, new products and freebies in your inbox.